More threads by David Baxter PhD

David Baxter PhD

Late Founder
FDA Approves New Treatment for Alcoholism
July 30, 2004

WASHINGTON (AP) - The government approved the first new drug to treat alcohol abuse in a decade on Thursday, a medicine called Campral that promises to help ward off relapses.

Campral, known chemically as acamprosate, isn't for patients who are actively drinking at the start of treatment or who abuse other substances in addition to alcohol, the Food and Drug Administration warned.

Exactly how Campral works isn't fully understood. But it is thought to somehow ease alcoholism withdrawal symptoms by normalizing abnormalities in two brain chemical systems.

In a study comparing Campral to a dummy pill, more of the people using Campral were continuously abstinent throughout their alcohol-abuse treatment, FDA said - although officials late Thursday couldn't provide the numbers to show how big the difference was.

Most common side effects were headache, diarrhea, flatulence and nausea, FDA said.

Campral, made by France's Lipha Pharmaceuticals, has been widely used in Europe for years. In the United States, there are two other FDA-approved drugs for alcohol abuse treatment: Antabuse, which reacts with alcohol to make the drinker violently ill, and naltrexone, which blocks brains chemicals that make alcoholics feel good after a drink.

Campral will be distributed in the United States by Forest Laboratories, which did not immediately reveal a price.
 

Similar threads

It used to be thought that children would "grow out of" ADHD by about age 14 or 15. We no know this to be false. Children (correctly) diagnosed with ADHD grow up to be adults with ADHD. That of course may be related more to temperament or emotional sensitivity that to the medication.
Replies
2
Views
2K
FDA Approves Once-Monthly Treatment for Schizophrenia By Caroline Cassels Mar 01, 2013 The US Food and Drug Administration (FDA) has approved long-acting aripiprazole (Abilify Maintena, Otsuka/Lundbeck) for the maintenance treatment of adults with schizophrenia. A once-monthly intramuscular (IM) depot formulation, the drug has the same efficacy and safety profile as the oral formulation, the manufacturers report. The FDA approval follows positive results of a phase 3 double-blind...
Replies
0
Views
1K
https://www.formularywatch.com/view/the-fda-approves-ultomiris-for-myasthenia-gravis April 28, 2022 Formulary Watch Vivjoa is an oral therapy and the first for chronic yeast infections. It is expected to be available in the second quarter of 2022. The FDA has approved Vivjoa (oteseconazole capsules), an azole antifungal to reduce the incidence of chronic yeast infection in postmenopausal women. This is the first approval for Mycovia Pharmaceuticals, which is developing therapies for fungal...
Replies
0
Views
198
FDA Approves Transdermal Patch for Migraine Medscape Medical News Laurie Barclay, MD Jan 18, 2013 The U.S. Food and Drug Administration (FDA) has approved sumatriptan iontophoretic transdermal system (Zecuity, NuPathe Inc) for acute treatment of adults who have migraine with or without aura. The single-use, battery-powered patch offers relief of migraine-related nausea (MRN) as well as migraine headache pain. Of 16 million U.S. adults diagnosed and treated with migraine, 8 million have MRN...
Replies
0
Views
1K
On a lighter note, Steve Martin joked that such a list could include winning online poker.
Replies
1
Views
3K
Top